Spectrum Pharma Receives FDA Approval for ROLVEDON antiinfective

 Spectrum Pharmaceuticals Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that the U.S. Food and Drug Administration (FDA) has approved ROLVEDON™ (eflapegrastim-xnst) injection to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with clinically significant incidence of febrile neutropenia.

https://www.biospace.com/article/releases/spectrum-pharmaceuticals-receives-fda-approval-for-rolvedon-eflapegrastim-xnst-injection/